To the Editor: In human hematopoietic stem and progenitor cells (HSPCs), TP53 mutations characterize clonal hematopoiesis of indeterminate potential (CHIP) and are recognized as a high-risk factor for the development of non-neoplastic and neoplastic disorders, particularly myelodysplastic syndromes (MDS) and acute myeloid leukemia [1, 2].
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Albert
Contact Albert, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack